A case of therapy-related acute myeloid leukemia with inv(16)(p13.1q22) after single low-dose iodine-131 treatment for thyroid cancer

Ji Hun Jeong1, Jeong Yeal Ahn1, Soon Ho Park1, Mi Jung Park1, Kyung Hee Kim1, Jun Shik Hong2
Departments of 1Laboratory Medicine, 2Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea

Radioiodine is regularly used in the treatment of thyroid cancer to eliminate residual malignant tissue after thyroidectomy and to treat metastasis. Because of the low dose of radioiodine used to treat thyroid cancer patients, leukemia is an uncommon complication of exposure to radioiodine. Here, we present a patient who developed therapy-related acute myeloid leukemia with inv(16)(p13.1q22);CBFβ-MYH11, eosinophilia, and K-ras mutation and who had been treated with very low-dose radioiodine following total thyroidectomy.

Key Words Radioiodine, Thyroid cancer, Acute myeloid leukemia, CBFβ-MYH11, Eosinophilia, K-ras

INTRODUCTION

Therapy-related acute myeloid leukemia (t-AML) caused by radioactive iodine (RAI) occurs in less than 2% of thyroid cancer patients and is associated with a poor therapeutic response and prognosis [1-3]. Many cases of t-AML have occurred in >50-year-old patients after they received a cumulative radioiodine dose of more than 800 mCi, with intervals of less than 12 months between 131I therapies [1-3]. Over 90% patients with t-AML or therapy-related myelodysplastic syndrome (t-MDS) exhibit an abnormal karyotype with approximately 70% patients having an unbalanced chromosomal aberration and the remaining 30% having a balanced chromosomal translocation [4]. Inv(16)(p13.1q22) is found in approximately 5-8% of patients with de novo acute myeloid leukemia (AML), but it is rarely reported in patients with t-AML. In 20-30% of t-AML patients, the first manifestation is AML without a preceding myelodysplastic phase [4].

Here, we report the case of a 38-year-old woman who developed t-AML with inv(16)(p13.1q22). CBFβ-MYH11, markedly increased eosinophils, and K-ras mutation were noted after treating her for thyroid cancer with a single low intensity dose of 131I.
Fig. 1. Morphologic and cytogenetic study. (A) Peripheral blood smear and (B) bone marrow aspirates show myeloblasts, immature monocyte precursors, and abnormal eosinophils. The eosinophil count is markedly increased (53.4%), and some eosinophils have basophilic granules (Wright Giemsa stain ×1,000). (C) Blasts are positive for myeloperoxidase (MPO). (D) The marrow monocytic component is stained by α-naphthyl-butyrate esterase. (E) The karyotype reveals 46,XX,inv(16)(p13.1q22)[20] (GTL banding, ×1,000). (F) FISH using a LSI CBFB Dual Color Break Apart Rearrangement Probe reveals separate red (5′CBFB gene) and green (3′CBFB gene) signals, resulting in distinct hybridization signals on the arm of the inverted chromosome 16, and these signals were expressed in more than 89% of the cells. The normal CBFB allele is seen as one fused red-green (yellow) signal.

for CD45, CD34, myeloperoxidase (MPO), CD13, CD33, CD117, CD14, and HLA-DR, while the other population showed positivity for CD45, MPO, CD13, CD33, CD14, and HLA-DR. Blasts cells were stained for MPO and α-naphthylbutyrate esterase (Fig. 1C and 1D). BM cytogenetic analysis showed inv(16)(p13.1q22) in 20 analyzed metaphases (Fig. 1E). The result of fluorescence in situ hybridization (FISH) revealed that 89% of the nucleated cells had an abnormal break-apart signal pattern, that is, nucish(CBFBx2) (5′CBFB-sep3CBFBx1)|356/400| (Vysis Inc., IL, USA; Fig. 1F). In the molecular study, gene rearrangements such as PML/RARA, AML1/ETO, and BCR/ABL, and a mutation in the FLT3 gene (ITD or D835Y) were negative. The K-ras mutation in codon 12 (G>A transition, GGT→GAT) was detected by the pyrosequencing method, and this mutation induced an amino acid change of wild-type glycine (G) to aspartic acid (D) (TheraScreen NRAS/KRAS Pyro kit, QIAGEN, Hamburg, Germany). The mutant allele burden in BM mononuclear cells was 42% (Fig. 2A). Based on the World Health Organization’s (WHO) 2008 criteria, the condition was diagnosed as t-AML with inv(16)(p13.1q22); CBFB-MYH11.

Blasts in peripheral blood and BM decreased rapidly after induction chemotherapy with cytarabine (100 mg/m² for 7 days) and idarubicin (12 mg/m² for 3 days), and the K-ras mutation, and the inv(16) rearrangement disappeared (Fig. 2B). The first consolidation therapy with cytarabine (100 mg/m² twice a day (b.i.d.) for 4 days) and daunorubicin (45 mg/m² for 3 days), and the second consolidation therapy with cytarabine (100 mg/m² b.i.d. for 4 days) and idarubicin (12 mg/m² for 3 days) were performed without serious complications. After the third consolidation therapy using high-dose cytarabine (3,000 mg/m² b.i.d. for 3 days), the
**DISCUSSION**

RAI therapy has been the treatment of choice for toxic nodular goiter, Grave disease, and metastatic thyroid cancer. The National Thyroid Cancer Treatment Co-operative Group recently reported that RAI treatment in thyroid carcinoma had been administered in 62-75% of individuals in a cohort study [5]. Meta-analysis using 16,502 patients showed that the relative risk (RR) of second primary malignancy was increased in thyroid cancer patients treated with $^{131}$I (RR=1.19), and that the RR for the development of leukemia was increased by 2.5-fold in thyroid cancer patients treated with RAI [1].

Even though leukemia is a rare complication of $^{131}$I therapy in these patients, the possible carcinogenic effect of $^{131}$I is still a concern. Pochin described 4 cases of acute leukemia in 175 patients treated with $^{131}$I for thyroid cancer, observing a leukemia incidence of 2.3% [2]. One group reported a case that the latency period from exposure to the occurrence of acute leukemia was 14 months [6]. The patient described here had received only a single dose of 150 mCi, and she developed AML in a shorter latency period than that seen in other t-AML cases. Moreover, Roldán reported 2 cases of AML, that is, AML with maturation (M2, French-American-British (FAB) classification) and acute promyelocytic leukemia, after a single dose of 150 mCi in patients who were diagnosed with papillary thyroid carcinoma. The latency periods of these 2 patients were 2 and 5 years, respectively [7].

Another report by Anderson et al. focused on 48 patients who had a history of other primary disease such as breast cancer, lymphoma, or various other solid tumor and non-malignant disease, and were diagnosed with t-MDS/t-AML with inv(16). Ten of these patients (20.8%) received radiation therapy only, and inv(16) is more frequent in patients treated with only radiotherapy [8]. Patients with inv(16) exhibited a shorter latency period from the start of treatment for the primary tumor to the development of t-MDS/t-AML than did patients with other therapy-related diseases (median, 22 months; range, 8-533 months). Within the inv(16) subgroup, patients younger than 55 years of age had a longer survival period compared with patients older than 55 years of age [8]. However, Schroeder et al. had suggested that t-MDS/t-AML after RAI treatment was usually associated with an advanced disease stage, adverse chromosomal changes, a low response to induction chemotherapy, and a short overall survival even with the numerous treatment options [9].

---

**Fig. 2.** K-ras mutation by pyrosequencing. Pyrogram shows the mutation and mutated clones. The X axis means the base and the Y axis represents the intensity of fluorescent signal. Shaded regions represent K-ras codons 12 and 13. (A) Arrow shows the analytic results of substitutions in the second base of K-ras codon 12. The mutation GGT (Gly) to GAT (Asp) in codon 12 was detected by pyrosequencing. (B) After induction of chemotherapy, the K-ras mutation disappeared.
Based on these findings, the patient presented here may be expected to have a poor outcome despite the presence of less severe risk factors such as inv(16) and young age. However, in the previous study, the t-AML with inv(16) (p13.1q22) or t(16;16)(p13.1;q22) was morphologically identical to its de novo counterpart [4], while in the current case, the patient revealed strikingly increased eosinophils (53.4%) compared with eosinophilia in de novo AML with inv(16) that ranged from 1% to 33% [10]. The eosinophils had characteristically coarse, purple-violet colored granules that were larger than those of normal eosinophils (Fig. 1B). Importantly, Pulsoni et al. previously demonstrated that eosinophilia is a favorable prognostic factor and that the concomitant presence of both inv(16) and eosinophilia is associated with a significantly improved prognosis [11].

The common Ras gene mutation is a one base substitution in codon 12, 13, or 61 leading to constant activity of the Ras protein, which is caused by the guanosine triphosphate-bound status and can induce uncontrolled cell proliferation and escape from apoptosis [12]. The frequency of K-ras mutations at codon 12, 13, or 61 in AML patients has been reported to range from 3.5% to 13.3%. In a study by Valk et al., K-ras mutations in codon 12 were found in 7% of the patients with AML and inv(16) [13]. The in vitro data suggest that mutant Ras promotes a myeloid maturation defect with relative sparing of the monocyte-macrophage lineage. This may be consistent with the overrepresentation of Ras mutations in the acute myelomonocytic leukemia (M4)/acute monoblastic and monocytic leukemia (M5) FAB types [14].

Based on these observations, Gilliland proposes a two-hit theory for leukemogenesis in which AML arises from the collaboration between 2 classes of mutations [15]. Class I mutations confer a proliferative and/or survival advantage to cells (BCR-ABL fusion gene and oncogenic Ras), while Class II mutations impair hematopoietic differentiation and apoptosis (CBFβ-MYH11 and PML-RARα fusion gene) [15]. The patient described here had both a K-ras mutation and inv(16) at the time of t-AML diagnosis, and these abnormalities were not detected after achieving complete remission. It can be presumed that these findings support the two-hit model of leukemogenesis, and that K-ras mutation and inv(16) correlate with leukemogenesis in this patient.

In conclusion, only a small proportion of thyroid cancer patients treated with radioiodine have developed leukemia, and different dose ranges and latent periods have been reported in various trials. The case presented here is a rare case of inv(16) in t-AML that developed after a single low-dose iodine therapy. Although the risk of leukemia after 131I exposure is hardly considered a contraindication to 131I therapy, hematological follow-up of patients admitted for 131I treatment is recommended.

REFERENCES

1. Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009;19:451-7.
2. Pochin EE. Prognostic factors from the treatment of thyroid carcinoma with radioiodine. Clin Radiol 1967;18:113-25.
3. Pochin EE. Leukaemia following radioiodine treatment of thyrotoxicosis. Br Med J 1960;2:1545-50.
4. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC, 2008:112-29.
5. Jonklaas J, Sarli S, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229-42.
6. Bitton R, Sachmechi I, Benegalao Y, et al. Leukemia after a small dose of radioiodine for metastatic thyroid cancer. J Clin Endocrinol Metab 1993;77:1423-6.
7. Roldán Schilling V, Fernández Abellán P, Domínguez Escrivano JR, Rivas González C, Mut Barberá E, Calatayud Cendra R. Acute leukemias after treatment with radioiodine for thyroid cancer. Haematologica 1998;83:767-8.
8. Andersen MK, Larson RA, Mauritsson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:395-400.
9. Schroeder T, Kuendgen A, Kayser S, et al. Therapy-related myeloid neoplasms following treatment with radioiodine. Haematologica 2012;97:206-12.
10. Le Beau MM, Larson RA, Bitter MA, et al. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia: A unique cytogenetic-clinopathological association. N Engl J Med 1983;15:309:630-6.
11. Pulsoni A, Iacobelli S, Bernardi M, et al. M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. Haematologica 2008;93:1025-32.
12. Arozarena I, Calvo F, Crespo P. Ras, an actor on many stages: posttranslational modifications, localization, and site-specified events. Genes Cancer 2011;2:182-94.
13. Valk PJ, Bowen DT, Frew ME, Goodeve AC, Löwenberg B, Reilly JT. Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16). Haematologica 2004;89:106.
14. Darley RL, Burnett AK. Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors. Exp Hematol 1999;27:1599-608.
15. Gilliland DG. Hematologic malignancies. Curr Opin Hematol 2001;8:189-91.